IP Library Granted Patent US 8,962,808
Granted Patent B2
US 8,962,808 · App. 13/696,291 · Granted Feb 24, 2015

EGFR-related polypeptides and methods of use

Inventors: Edward L. Chan (Mt. Sinai, NY); James Keller (Islip, NY)
Assignee: The Research Foundation for the State University of New York
C12Q1/6886C07K14/71G01N33/57407C07K16/40C12N9/12G01N33/74C07K2319/00C07K2319/23C07K2319/42C07K2319/43C07K2319/60G01N2333/71G01N2800/56
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,962,808
App. No.
13/696,291
Granted
Feb 24, 2015
Kind
B2
Abstract

Described herein are truncated EGF receptor polypeptides, nucleic acids encoding them, and methods of using them to help select a method of treatment for an EGFR-related cancer, to predict clinical outcome, and to detect micrometastases or minimal residual disease. High EGFR expression and phosphorylated EGFR predicts poor survival in head and neck cancer patients, but does not correlate with advanced stage disease. In our studies, we determined that clinical biological correlates are likely to be more accurate when different aspects of EGFR are evaluated in combination. We analyzed EGFR phosphorylation, expression and mutations in 60 primary head and neck tumors. We not only found that head and neck tumors with either truncated or activated EGFR tend to have higher tumor and nodal stage, but also discovered three EGFR truncations.

Claims (4)

1. A purified antibody that specifically binds to an epitope in the extracellular domain of EGFRΔ768.

2. The antibody of claim 1 , wherein the epitope is encoded by a 20 base pair nucleic acid sequence spanning the splice junction between nucleotide 102 of exon 2 and nucleotide 869 of exon 7.

3. The antibody of claim 2 , wherein the nucleic acid sequence comprises the sequence 5′TGCCAAGGCACCTGCGTG3′ (SEQ ID NO: 13).

4. A kit comprising a measured amount of the antibody of claim 1 .

Assignments (3)
CONFIRMATORY LICENSE Recorded Apr 16, 2015
From: STATE UNIVERSITY NEW YORK STONY BROOK
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 035446/0336 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 8, 2014
From: CHAN, EDWARD L.; KELLER, JAMES
To: THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
Reel/Frame 033257/0314 →
CHANGE OF NAME Recorded Feb 21, 2014
From: RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK, THE
To: RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK, THE
Reel/Frame 032323/0277 →
Continuity (2)
Provisional Application 61331815 · May 5, 2010
Related Publication 20130210004A1 · Aug 15, 2013